EAU 2013 - Programme Book - YouMed

Sunday, 17 March - EAU Programme
Abstract Session
09.15 - 10.45 Prostate cancer: Active surveillance
Brown Hall 1-2 - Level S2
Poster Session 23
Chairs: L.M. Campos Pinheiro, Lisboa (PT)
T.M. De Reijke, Amsterdam (NL)
Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes
in length, followed by 2 minutes for discussion. Extended presentations (*) are 4 minutes in length, followed
by 2 minutes for discussion.
* 265 Monitoring of three-dimensionally mapped biopsy-proven image-visible lesions of prostate cancer on
active surveillance: 11 year experience
S. Shoji, O. Ukimura, A.L. De Castroabreu, S. Leslie, T. Uchida, I. Gill, D. Bahn (Los Angeles, United States of
America; Hachioji, Japan)
* 266 Role of multiparametric 3.0 Tesla magnetic resonance imaging in prostate cancer patients eligible for
active surveillance
B.H. Park, S.H. Choo, H.J. Jang, Y.S. Suh, U.S. Jeong, W. Song, H.G. Jeon, B.C. Jeong, S.I. Seo, S.S. Jeon,
H.Y. Choi, K.S. Lee, H.M. Lee (Seoul, South Korea)
267 Radiological progression in men with prostate cancer on active surveillance
A.J. Ridout, D. Stevens, C. Allen, A. Kirkham, A. Freeman, C. Jamieson, M. Emberton, C.M. Moore (London,
United Kingdom)
268 Impact of multiparametric prostate MRI on the selection of active surveillance patients
F. Sanguedolce, A.R. Padhani, N. Anyamene, J. Beatty, G. Hellawell (London, United Kingdom)
269 Low risk prostate cancer patients without visible tumor (T1c) on diffusion-weighted MRI could qualify for
active surveillance candidate regardless of inclusion criteria of active surveillance protocol
D.H. Lee, K.H. Kim, S.H. Lee, K.H. Rha, Y.D. Choi, S.J. Hong, B.H. Chung (Seoul, South Korea)
270 The significance of finding no prostate cancer on the active surveillance confirmatory biopsy: Implications
for pathological re-classification
L.M. Wong, G. Trottier, N. Lawrentschuk, N.E. Fleshner, G. Kulkarni, A.R. Zlotta, J. Trachtenberg, A. Toi,
N. Timilshina, A. Finelli (Toronto, Canada)
271 The value of histological revision of biopsy cores in patients suitable for active surveillance: Comparison
with surgical specimens after radical prostatectomy and clinical follow-up
R. Schiavina, M. Fiorentino, E. Brunocilla, M.S. Rossi, S. Rizzi, D. Romagnoli, L. Bianchi, M. Borghesi,
D. Diazzi, H. Dababneh, G. Passaretti, G. Martorana (Bologna, Italy)
272 The HAROW study - an observational health service study, capturing current low-risk-prostate cancer
treatment practice patterns in Germany
A. Becker, L.A. Kluth, S. Beermann, D. Seiler, F. Recker, F.K. Chun, L. Weissbach (Hamburg, Berlin, Germany;
Aarau, Switzerland)
* 273 Is PSA doubling time reliable as a progression risk criterion for patients with low-risk prostate cancer in
an active surveillance programme?
F.B. Thomsen, I.J. Christensen, M.A. Røder, K. Brasso, P. Iversen (Copenhagen, Denmark)
EAU Milan 2013
147
Sunday